Crossject gained almost 7% on the Paris Bourse on Tuesday, after successfully passing European and American audits for the manufacture of its auto-injector for the treatment of epileptic seizures.

The company announced this morning that its French production sites based in Dijon and Gray had received a positive assessment following the audit conducted by the US Biomedical Advanced R&D Authority (BARDA) on the conformity of the system's manufacture for the US market.

"The success of these audits demonstrates once again the rigorous standards of the Group's manufacturing systems", reacted analysts at Invest Securities this morning.

As a reminder, the company has signed a $60 million contract with BARDA to supply the Zeneo Midazolam needle-free injection system as soon as it has been approved by the FDA, the US health authority, which is expected by the end of the year.

Under the terms of the contract, BARDA also has the option of purchasing additional units, up to a maximum of $59 million.

The total contract value, if all options are exercised, is $155 million.

Crossject's two sites have also successfully passed an annual ISO certification audit, extending their scope of certification by the Agence nationale de sécurité du médicament et des produits de santé (ANSM).

In addition, the British Standards Institution (BSI), a notified body, has renewed its ISO certification following its annual audit of Crossject's quality systems.

Copyright (c) 2023 CercleFinance.com. All rights reserved.